Company intelligence / Profile preview

Rhino Novi

Durango, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Rhino Biotech has established robust R&D and a commercial pipeline of nutraceuticals, functional beverages, and veterinary products, with ongoing university collaborations and initial clinical trials in cannabinoid-based pharmaceutical candidates; revenue in 2022 projected at $8.2–$16.4 million, with ongoing expansion in proprietary cultivars. Clinical results for prescription products not yet published; some veterinary and nutritional products claim peer-reviewed validation.

Therapeutic areas: Other
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Collaborations with major medical and agricultural research institutions (specific names not disclosed)

Beyond the preview

Go deeper on Rhino Novi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhino Novi.

Explore the full profile